OpenAI acquires Orchestra Bio to build AI agents that speed up drug development

What happened

OpenAI acquired Orchestra Bio, a startup that helps pharmaceutical teams coordinate drug development, and will integrate it into its Rosalind life sciences platform. Orchestra's agents track trials, flag timeline disruptions such as failed production batches, and suggest next steps. The combined effort aims to connect scientific findings with clinical trials and decisions to get drugs to patients faster; financial terms were not disclosed.

Read next

• More changes in today’s briefingConfigure the ChatGPT desktop app with Amazon Bedrock in AWS GovCloud (US)

Reported by 5 sources

The story so far

OpenAI said it has acquired Orchestra Bio, bringing a platform for coordinating drug development into its life sciences work. Its website announcement described the acquisition as in progress, while its later post on X said it was complete; TechCrunch and The Decoder also reported it as completed. Orchestra builds AI agents that track finances and resolve clinical trial scheduling issues, according to TechCrunch. The Decoder reported that its agents also track trials, flag disruptions such as failed production batches, and suggest next steps. These tools address the operational work involved in developing drugs. TechCrunch reported that OpenAI said Orchestra’s team and technology will contribute to Rosalind, its life sciences research model, and Rosalind Workbench, a tool intended to help researchers plan experiments and analyze results. The Decoder described the acquisition as being integrated into the Rosalind platform. OpenAI said the combined effort aims to streamline biopharma teams’ operations and help new treatments reach patients.